Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RELENT

Financiado

Cerrado

RELapses prevENTion in chronic autoimmune disease common mechanisms and co morb...

RELapses prevENTion in chronic autoimmune disease common mechanisms and co morbidities RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mor... ver más

30/04/2020

MEDIZINISCHE UNIVE...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-04-30

PHC-03-2015: Understanding common mechanisms of...

I+D

Cerrada hace 10 años

0% 93% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

MEDIZINISCHE UNIVERSITAET WI...

1.13M€ | Lider

CENTRO MEDICO VIRGEN DE LA C...

243.86K€ | Participante

Mayo Clinic

GABO:mi

38.58K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RIISPAD Role of innate immunity in the pathogenesis of autoimmune di... 100K€ Cerrado

PREVENT RA Towards prevention of autoimmune diseases the case of rheum... 2M€ Cerrado

INTRICATE Infectious triggers of chronic autoimmunity 8M€ Cerrado

PREVENTRA Genes environment and immunity in the pathogenesis of rheum... 2M€ Cerrado

RTC-2015-3562-1 Desarrollo y Validación clínica de un sistema de análisis de... 49K€ Cerrado

OSTEOIMMUNE OSTEOIMMUNE Unraveling the Interactions between the Immune... 3M€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2015-12-09
Fecha Fin: 2020-04-30

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto RELENT is multidisciplinary group of scientists and clinical investigators whose goal is to develop individualized treatment for chronic autoimmune diseases, such as rheumatoid arthritis and vasculitis, that cause considerable mortality and morbidity, both from uncontrolled disease and treatment associated co-morbidities, like infection and malignancy. This requires the need to stratify patients by their outcome and to tailor immunosuppression based on much deeper knowledge of the mechanisms that control initiation and persistence of the pathogenic immune responses. The RELENT Consortium has been formed to generate this knowledge with the ultimate goal of developing treatments tailored to the specific needs of individual patients. RELENT combines the resources of seven leading European Investigators and two from US and Australia whose expertise is not available elsewhere in the world but necessary for the ambitious work program. Three SMEs will supply specific reagents and translate the results to biomarker development. This will enable RELENT to deliver its four specific research aims, namely to: i) Combine subset analysis of genome wide association studies with classical cell biology to uncover pathways that influence and ii) use multiplexed antigen arrays, whole proteome analysis and rapid mass analysis to identify protein signatures that predict outcome and response to treatment in chronic autoimmune disease. iii) Characterise T and B cell abnormalities that predispose to autoimmunity and infection by studying the ageing immune system in health and disease. iv) Analyse pathogenic effector T cells and their control by macrophages and dendritic cells and the molecules they secrete using in vivo models. We anticipate to identify common mechanisms responsible for the persistence and outcomes in severe autoimmune and inflammatory diseases in females and males and that the results should be rapidly translatable into clinical practice for the benefit of patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores